SMS Pharmaceuticals Limited

BSE: 532815 NSE: SMSPHARMA
SMS Pharmaceuticals Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L24239TG1987PLC008066 Incorporated 14 December 1987 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: SMSPHARMA · BSE: 532815 Public Limited Company pharma
Data last updated
Market Cap
₹4,184 Cr
SMSPHARMA · NSE
Share Price
₹444.65
-0.47% today
Revenue
₹887 Cr
FY 2025-26 · +13.3% YoY
EBITDA
₹171 Cr
Margin 19.3%
Net Profit
₹102 Cr
FY 2025-26 · +47.5% YoY
P/E (TTM)
42.9x
P/B 5.6x
Authorised capital
₹12 Cr
Registered with MCA
Paid-up capital
₹9.37 Cr
Issued & subscribed

About SMS Pharmaceuticals Limited

Data last updated:

SMS Pharmaceuticals Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 14 December 1987 and has been in existence for over 39 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24239TG1987PLC008066. Its GSTIN is 36AADCS2221D1ZX (Telangana). The company holds 4 GST registrations, of which 3 are active. Its shares are listed on BSE: 532815 and NSE: SMSPHARMA.

The company has an authorised share capital of ₹12 Cr and a paid-up capital of ₹9.37 Cr. It was formerly known as S.M.S. Pharmaceuticals Private Limited and Sms Pharmaceuticals Pvt Limited. It is led by directors including Ramesh Babu Potluri (Managing Director) and Vamsi Krishna Potluri (Whole-Time Director).

Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 8th Floor Trendset Jayabheri Connect, Hyderabad, Telangana, India – 500084.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹886.87 Cr, a growth of 13.3% compared to the previous year. For the same year it recorded a net profit of ₹101.98 Cr (net margin 11.5%) and EBITDA of ₹171.28 Cr (EBITDA margin 19.3%).

The company has about 1,193 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Sms Pharmaceuticals. As per MCA filings, the company has open charges of ₹786.13 Cr and satisfied charges of ₹640.7 Cr on record. Court records list 76 cases involving the company, including 45 filed by the company and 27 filed against it; 10 cases are pending. The company has 52 deals on record (50 market trades, 1 acquisition, 1 ipo); the latest was in November 2025. Its 10 peer companies in the Pharma industry (API Manufacturers, Pharmaceuticals) are compared by revenue, 5 larger and 5 smaller; the largest is Virupaksha Organics Limited with revenue of ₹816.52 Cr.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website smspharma.com.

Company Details of SMS Pharmaceuticals Limited
CIN L24239TG1987PLC008066
Registration Number 008066
Incorporation Date 14 December 1987
ROC Hyderabad
Listing Status Listed (BSE: 532815, NSE: SMSPHARMA)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Ramesh Babu Potluri Managing Director Vamsi Krishna Potluri Whole-Time Director Shravan Kudaravalli Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    smspharma.com
  • Social Media
    Locked
  • Registered Address
    8th Floor Trendset Jayabheri Connect, Hyderabad, Telangana, India – 500084
  • Industry
    Pharma, API Manufacturers
Comprehensive company report
SMS Pharmaceuticals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full SMS Pharmaceuticals Limited report

Financials, compliance, directors, charges, ownership and filings for SMS Pharmaceuticals Limited in one report.

Financials from 2015 Directors & ownership Charges & compliance

Business Activity of SMS Pharmaceuticals Limited

The main business activity of SMS Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Financials of SMS Pharmaceuticals Limited FY 2025-26 filings available

SMS Pharmaceuticals Limited reported revenue of ₹886.87 Cr (up 13.3% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹887 Cr
+13.3% YoY
EBITDA
₹171 Cr
+23.2% YoY
Profit After Tax
₹102 Cr
+47.5% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue887783709522520563412
Revenue growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
EBITDA17113911754.5511512180.03
EBITDA margin+19.3%+17.8%+16.5%+10.5%+22.1%+21.5%+19.4%
Profit before tax11792.3366.115.3668.5091.1250.75
Net profit10269.1249.80(7.01)62.2262.5331.60
Net profit margin+11.5%+8.8%+7.0%-1.3%+12.0%+11.1%+7.7%
EPS (₹)11.157.805.89(0.83)7.357.393.73
Balance sheet
Total assets-952818716735667507
Net worth-640536461470411348
Total debt-311281254263255157
Cash & bank-41.5936.207.4746.6640.519.65
Net working capital-401361288292218158
Cash flow
Cash from operations-81.7150.1222.4545.0690.4539.71
Cash from investing-(123)(52.07)(29.76)(27.15)(152)(42.56)
Cash from financing-47.0830.68(31.97)(11.75)92.02(2.40)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue207238210242196248173197
Revenue growth (YoY)+5.6%-4.1%+21.4%+23.2%+19.2%---
Other income1.742.573.751.430.591.422.131.30
EBITDA40.9539.9043.6548.3739.3740.8133.2131.47
EBITDA margin+19.8%+16.8%+20.7%+20.0%+20.1%+16.4%+19.2%+16.0%
Depreciation9.9910.1310.0210.029.758.648.708.62
Interest5.505.286.225.745.845.074.204.61
Profit before tax27.2027.0631.1634.0424.3728.5222.4419.54
Tax7.006.107.978.915.658.445.365.68
Net profit20.2020.9623.1925.1318.7220.0817.0813.86
EPS (₹)2.233.582.592.842.312.402.151.67
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue887783709522520563412
Revenue growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
EBITDA17114011754.7511512180.03
EBITDA margin+19.3%+17.9%+16.5%+10.5%+22.1%+21.5%+19.4%
Profit before tax11693.3066.335.5668.6591.1250.75
Net profit87.6068.3549.394.1368.0360.9732.71
Net profit margin+9.9%+8.7%+7.0%+0.8%+13.1%+10.8%+7.9%
EPS (₹)9.587.715.840.488.047.203.86
Balance sheet
Total assets-985852751759685526
Net worth-673570495494428367
Total debt-311281254263255157
Cash & bank-41.5836.207.4746.6640.519.65
Net working capital-401361288292218158
Cash flow
Cash from operations-81.7150.1222.4545.0690.4539.71
Cash from investing-(123)(52.07)(29.76)(27.15)(152)(42.56)
Cash from financing-47.0830.68(31.97)(11.75)92.02(2.40)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue207238210242196248173197
Revenue growth (YoY)+5.6%-4.1%+21.4%+23.2%+19.2%---
Other income1.742.573.751.430.591.422.131.30
Total expenses165198167194157207140165
EBITDA41.8939.8843.8048.3838.8641.3533.3031.86
EBITDA margin+20.2%+16.8%+20.8%+20.0%+19.8%+16.7%+19.2%+16.2%
Depreciation9.9910.1310.0210.029.758.648.708.62
Interest5.505.286.225.745.845.074.204.61
Profit before tax28.1427.0431.3134.0523.8629.0622.5319.93
Tax7.016.127.978.915.658.445.365.68

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 09 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue207238210242196248173197
Revenue growth (YoY)+5.6%-4.1%+21.4%+23.2%+19.2%---
Other income1.742.573.751.430.591.422.131.30
EBITDA40.9539.9043.6548.3739.3740.8133.2131.47
EBITDA margin+19.8%+16.8%+20.7%+20.0%+20.1%+16.4%+19.2%+16.0%
Depreciation9.9910.1310.0210.029.758.648.708.62
Interest5.505.286.225.745.845.074.204.61
Profit before tax27.2027.0631.1634.0424.3728.5222.4419.54
Tax7.006.107.978.915.658.445.365.68
Net profit20.2020.9623.1925.1318.7220.0817.0813.86
EPS (₹)2.233.582.592.842.312.402.151.67
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue887783709522520563412
Revenue growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
Other income8.356.224.464.915.203.455.11
Total expenses716644592468405442332
Employee cost0.0080.0864.1550.0851.0241.1739.35
EBITDA17113911754.5511512180.03
EBITDA margin+19.3%+17.8%+16.5%+10.5%+22.1%+21.5%+19.4%
Depreciation39.9234.3431.5232.1332.1522.2822.07
Interest23.0818.5423.6021.9719.1611.1912.32
Profit before tax11792.3366.115.3668.5091.1250.75
Tax28.6424.9416.911.470.6230.1618.07
Net profit10269.1249.80(7.01)62.2262.5331.60
Net profit margin+11.5%+8.8%+7.0%-1.3%+12.0%+11.1%+7.7%
EPS (₹)11.157.805.89(0.83)7.357.393.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-8.878.478.478.478.478.47
Reserves & surplus-615499452462402340
Shareholders' funds (net worth)-640536461470411348
Minority interest-0.000.000.000.000.000.00
Secured loans-310279289259249151
Unsecured loans-1.201.79(34.84)4.355.265.98
Total debt-311281254263255157
Total liabilities-952818716735667507
Assets
Gross block-760631576571559361
Net block-533437412438457280
Capital work in progress-34.6730.2733.1911.006.7442.12
Investments-11.6810.9410.5221.5327.3025.81
Inventories-285234224251138129
Sundry debtors-20323614848.5210648.77
Cash & bank balances-41.5936.207.4746.6640.519.65
Loans & advances-24.9227.7631.3330.7825.3531.16
Total current assets-554534411377309219
Total current liabilities-15317312384.8391.4161.13
Net working capital-401361288292218158
Total assets-952818716735667507
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-36.047.3146.5840.429.5414.80
Net cash from operating activities-81.7150.1222.4545.0690.4539.71
Net cash from investing activities-(123)(52.07)(29.76)(27.15)(152)(42.56)
Net cash from financing activities-47.0830.68(31.97)(11.75)92.02(2.40)
Net change in cash-5.3628.73(39.28)6.1630.88(5.25)
Closing cash-41.5936.207.4746.6640.519.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
EBITDA growth+23.2%+19.0%+114.1%-52.4%-5.4%+51.4%-
PBT growth+26.3%+39.7%+1133.4%-92.2%-24.8%+79.6%-18.6%
Net income growth+47.5%+38.8%+810.4%-111.3%-0.5%+97.9%-
Revenue CAGR (3Y)+19.3%+14.6%+8.0%+8.2%+3.8%+6.8%-2.0%
EBITDA CAGR (3Y)+46.4%+6.6%-1.2%-12.0%+8.3%+9.1%+2.1%
Profitability & leverage
Net income margin+9.9%+8.6%+6.9%+0.8%+13.1%+10.8%+7.9%
Return on capital employed-+12.5%+11.7%+3.8%+12.5%+17.4%+13.0%
Return on net worth-+11.5%+9.9%+0.8%+15.4%+16.1%+9.8%
Debt / equity-0.500.540.560.590.540.45
Long-term debt / equity-0.220.280.330.340.290.20
Interest cover17.5717.7227.6897.9923.2411.3221.26
Efficiency & per share
Fixed asset turnover-1.201.250.970.981.331.29
Inventory turnover-3.223.292.342.864.583.41
Debtors turnover-3.803.915.637.207.9212.12
EPS (₹)11.157.805.89(0.83)7.357.393.73
Dividend per share (₹)0.400.400.400.300.300.300.25
Book value per share (₹)0.0070.3659.9854.4055.5648.5041.14
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue207238210242196248173197
Revenue growth (YoY)+5.6%-4.1%+21.4%+23.2%+19.2%---
Other income1.742.573.751.430.591.422.131.30
Total expenses165198167194157207140165
EBITDA41.8939.8843.8048.3838.8641.3533.3031.86
EBITDA margin+20.2%+16.8%+20.8%+20.0%+19.8%+16.7%+19.2%+16.2%
Depreciation9.9910.1310.0210.029.758.648.708.62
Interest5.505.286.225.745.845.074.204.61
Profit before tax28.1427.0431.3134.0523.8629.0622.5319.93
Tax7.016.127.978.915.658.445.365.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue887783709522520563412
Revenue growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
Other income8.356.224.464.915.203.455.11
Total expenses716643592467405442332
Employee cost0.0069.7256.7850.0851.0241.1739.35
EBITDA17114011754.7511512180.03
EBITDA margin+19.3%+17.9%+16.5%+10.5%+22.1%+21.5%+19.4%
Depreciation39.9234.3431.5232.1332.1522.2822.07
Interest23.0818.5423.6021.9719.1611.1912.32
Profit before tax11693.3066.335.5668.6591.1250.75
Tax28.6624.9416.911.470.6230.1618.07
Net profit87.6068.3549.394.1368.0360.9732.71
Net profit margin+9.9%+8.7%+7.0%+0.8%+13.1%+10.8%+7.9%
EPS (₹)9.587.715.840.488.047.203.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-8.878.478.478.478.478.47
Reserves & surplus-648533487485420359
Shareholders' funds (net worth)-673570495494428367
Secured loans-310279289259249151
Unsecured loans-1.201.79(34.84)4.355.265.98
Total debt-311281254263255157
Total liabilities-985852751759685526
Assets
Gross block-760631576571559361
Net block-533437412438457280
Capital work in progress-34.6730.2733.1911.006.7442.12
Investments-45.1145.1045.1045.0045.0045.00
Inventories-285234224251138129
Sundry debtors-20323614848.5210648.77
Cash & bank balances-41.5836.207.4746.6640.519.65
Loans & advances-24.9227.7631.3330.7825.3531.16
Total current assets-554534411377309219
Total current liabilities-15317312384.8391.4161.13
Net working capital-401361288292218158
Total assets-985852751759685526
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-36.047.3146.5840.429.5414.80
Net cash from operating activities-81.7150.1222.4545.0690.4539.71
Net cash from investing activities-(123)(52.07)(29.76)(27.15)(152)(42.56)
Net cash from financing activities-47.0830.68(31.97)(11.75)92.02(2.40)
Net change in cash-5.3528.73(39.28)6.1630.88(5.25)
Closing cash-41.5836.207.4746.6640.519.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
EBITDA growth+22.1%+19.6%+113.7%-52.3%-5.3%+51.4%-
PBT growth+24.6%+40.7%+1093.0%-91.9%-24.7%+79.6%-18.6%
Net income growth+28.2%+38.4%+1095.9%-93.9%+11.6%+86.4%-
Revenue CAGR (3Y)+19.3%+14.6%+8.0%+8.2%+3.8%+6.8%-2.0%
EBITDA CAGR (3Y)+46.2%+6.8%-1.2%-11.9%+8.4%+9.1%+2.1%
Profitability & leverage
Net income margin+9.9%+8.7%+7.0%+0.8%+13.1%+10.8%+7.9%
Return on capital employed-+12.2%+11.2%+3.7%+12.2%+16.9%+12.5%
Return on net worth-+11.0%+9.3%+0.8%+14.8%+15.3%+9.2%
Debt / equity-0.480.500.520.560.520.43
Long-term debt / equity-0.210.260.310.330.280.19
Interest cover17.6217.5527.6197.1323.1911.3221.26
Efficiency & per share
Fixed asset turnover-1.201.250.970.981.331.29
Inventory turnover-3.223.292.342.864.583.41
Debtors turnover-3.803.915.637.207.9212.12
EPS (₹)9.587.715.840.488.047.203.86
Dividend per share (₹)0.400.400.400.300.300.300.25
Book value per share (₹)0.0074.1364.0258.4958.3350.5943.40
Want more history and ratios?
You're viewing the latest exchange-filed financials for SMS Pharmaceuticals Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Peer Comparison of SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
SMS Pharmaceuticals Limited this company₹886.87 Cr (FY 2026)••••••••13.3%••••Hyderabad, Telangana, India
Virupaksha Organics Limited₹816.52 Cr (FY 2025)••••••••6.0%••••Hyderabad, Telangana, India
Abil Chempharma Private Limited₹795.2 Cr (FY 2025)••••••••6.0%••••Mumbai, Maharashtra, India
Symed Labs Limited₹791.92 Cr (FY 2025)••••••••6.0%••••Hyderabad, Telangana, India
Synokem Pharmaceuticals Limited₹791.15 Cr (FY 2025)••••••••0.0%••••New Delhi, Delhi, India
Sterile India Private Limited₹791.14 Cr (FY 2025)••••••••-13.0%••••New Delhi, Delhi, India
Prime Pharmaceuticals Private Limited₹783.06 Cr (FY 2025)••••••••131.0%••••Mumbai, Maharashtra, India
Symbiotec Pharmalab Limited₹755.98 Cr (FY 2025)••••••••5.0%••••Mhow, Madhya Pradesh, India
Helm India Private Limited₹736.7 Cr (FY 2025)••••••••40.0%••••Mumbai, Maharashtra, India
Tagoor Laboratories Private Limited₹719.28 Cr (FY 2022)••••••••55.0%••••Andhra Pradesh, India
Optimus Drugs Private Limited₹713.55 Cr (FY 2024)••••••••-41.0%••••Hyderabad, Telangana, India

Peers are the five companies nearest above and the five nearest below SMS Pharmaceuticals by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details of SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited is audited by SURYANARAYANA & SURESH for the financial year 2024.

NameStatusAppointment DateCessation Date
SURYANARAYANA & SURESHLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of SMS Pharmaceuticals Limited

SMS Pharmaceuticals has 8 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Shravan Kudaravalli
Also directs: CMH Tools Limited
Director26 May 20188 Years 4 MonthsCurrent
Srinivas SarvepalliDirector12 Aug 20197 Years 1 MonthsCurrent
Ramesh Babu Potluri
Also directs: Potluri Agri Farms LLP, SMS Peptides Private Limited, VKT Pharma Private Limited and 1 more
Managing Director01 Dec 200817 Years 10 MonthsCurrent
Vamsi Krishna Potluri
Also directs: SMS Peptides Private Limited, VKT Pharma Private Limited, Potluri Infra Projects LLP and 3 more
Whole-Time Director05 Jun 20206 Years 4 MonthsCurrent
Suresh Kumar GangavarapuDirector12 Aug 20242 Years 1 MonthsCurrent
Shanti Sree Bolleni
Also directs: Tukaram & Co LLP, Rain Industries Limited, Nile Limited and 5 more
Director12 Aug 20242 Years 1 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Shareholding Pattern of SMS Pharmaceuticals Limited

Shareholding for the quarter ended Sep 2026: promoters hold 68.10%, foreign institutional investors hold 0.60%, domestic institutional investors hold 2.90% and retail and other public shareholders hold 28.40%.

Promoters: 68.10%DII (Domestic Institutional): 2.90%FII (Foreign Institutional): 0.60%Retail & Others: 28.40%
Sep 2026
QUARTER
68.10% Promoters
2.90% DII (Domestic Institutional)
0.60% FII (Foreign Institutional)
28.40% Retail & Others
Promoter holding - history
Now 68.10% · Sep 2026High 68.10% · Dec 2025Low 68.10% · Dec 2025
67%67.8%68.5%69.3%70%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 68.10%Mar 2026: 68.10%Jun 2026: 68.10%Sep 2026: 68.10%68.10%68.10%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters68.10%68.10%68.10%68.10%
Public31.90%31.90%31.90%31.90%

Charges & Borrowings of SMS Pharmaceuticals Limited

Open charges
₹786.13 Cr
Satisfied charges
₹640.7 Cr
Breakdown by lending institutions
Others₹412.39 Cr
State Bank of India₹197.03 Cr
Idbi Bank Limited₹136.70 Cr
Axis Bank Limited₹40.00 Cr
Mid - West Leasing Ltd.₹0.01 Cr
Latest charge details
DateLenderAmountStatus
24 Feb 2026Others₹180 CrOpen
22 Oct 2025Axis Bank Limited₹40 CrOpen
14 Feb 2024Others₹100 CrOpen
24 Jan 2023Idbi Bank Limited₹25 CrOpen
08 Mar 2022Others₹16.09 CrOpen

Total charge records: 64 View all charges

Deals & Funding of SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has 52 deals on record (50 market trades, 1 acquisition, 1 ipo); the latest was in November 2025.

Total deals
52
Market trades
50
Acquisition
1
IPO
1

Deals on record (5 of 52)

WhenDealAmountParties
Sep 2025Market trade₹62.04 CrBuyer: Musigma Securities, Graviton Research Capital LLP , NK Securities Research Private Limited
Seller: Musigma Securities, Graviton Research Capital LLP , NK Securities Research Private Limited
Sep 2024Market trade₹24.9 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Mar 2024Market trade₹10.06 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Mar 2024Market trade₹10.39 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Mar 2024Market trade₹8.49 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Premium access

Full deal history

All 52 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Associated Brands with SMS Pharmaceuticals Limited

SMS Pharmaceuticals operates one associated brand: Sms Pharmaceuticals. Each brand links to its own profile.

BrandDescriptionWebsite
Sms Pharmaceuticals
Active pharmaceutical ingredients and intermediates are manufactured by SMS Pharmaceuticals.smspharma.com

Employees and EPFO Compliance at SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has a workforce of 1,193 employees as of Mar 23, 2024.

Employee count
1,193
Active EPFO establishments
2
Employee growth
8.55%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

Group Structure of SMS Pharmaceuticals Limited

SMS Pharmaceuticals has 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Associated companies

Name History of SMS Pharmaceuticals Limited

SMS Pharmaceuticals has undergone 2 name changes throughout its history. The company was previously known as S.M.S. Pharmaceuticals Private Limited, and Sms Pharmaceuticals Pvt Limited. The current legal name is Sms Pharmaceuticals Limited.

Company NameStatus
SMS Pharmaceuticals LimitedCurrent
S.M.S. Pharmaceuticals Private LimitedPrevious
Sms Pharmaceuticals Pvt LimitedPrevious

CIN History of SMS Pharmaceuticals Limited

SMS Pharmaceuticals has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24239TG1987PLC008066, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24239TG1987PLC008066Current
U24239AP1987PLC008066Previous
L24239AP1987PLC008066Previous

News related to SMS Pharmaceuticals Limited

Recent Activity on SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has 40 board changes on record since 1994: 24 appointments and 16 cessations. The latest: Shanti Sree Bolleni was appointed as Director on 12 Aug 2024.

Charges
A charge with Others amounted to Rs. 180.00 Cr with Charge ID 101242646 was registered on 24 Feb 2026.
Charges
A charge with Axis Bank Limited of Rs. 40.00 Cr registered on 22 Oct 2025 with Charge ID 101182903 was modified on 09 Jan 2026.
Charges
A charge with Others of Rs. 40.00 Cr registered on 24 Jun 2016 with Charge ID 100035079 was modified on 11 Nov 2025.
Charges
A charge with State Bank Of India of Rs. 173.83 Cr registered on 11 May 1989 with Charge ID 90260758 was modified on 11 Nov 2025.
Charges
A charge registered on 02 Nov 2023 via Charge ID 100819428 with Others was fully satisfied on 28 Oct 2025.
Charges
A charge with Axis Bank Limited amounted to Rs. 40.00 Cr with Charge ID 101182903 was registered on 22 Oct 2025.
AGM
Sms Pharmaceuticals Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Filing
Sms Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Charges
A charge with Idbi Bank Limited of Rs. 68.00 Cr registered on 11 Nov 2014 with Charge ID 10535013 was modified on 27 Mar 2025.
Charges
A charge registered on 16 Mar 2018 via Charge ID 100161678 with Others was fully satisfied on 06 Nov 2024.
Charges
A charge with Others of Rs. 100.00 Cr registered on 14 Feb 2024 with Charge ID 100866272 was modified on 22 Aug 2024.
Appointed
Shanti Sree Bolleni was appointed as Director.

188 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for SMS Pharmaceuticals Limited

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by SMS Pharmaceuticals Limited

Premium access

MSME payment history

Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of SMS Pharmaceuticals Limited

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of SMS Pharmaceuticals Limited

SMS Pharmaceuticals has 4 GST registrations: 3 active and 1 cancelled or inactive.

Total GSTINs
4
Active
3
Cancelled / inactive
1
GSTINStateStatusRegistered on
36AADCS2221D1ZXTelanganaActive01 Jul 2017
36AADCS2221D2ZWTelanganaActive25 Jul 2017
37AADCS2221D1ZVAndhra PradeshActive01 Jul 2017
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of SMS Pharmaceuticals Limited

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Frequently Asked Questions about SMS Pharmaceuticals Limited

SMS Pharmaceuticals is an active public limited company based in Hyderabad, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 14 December 1987 (39+ years old) and is registered under CIN L24239TG1987PLC008066. Listed on BSE: 532815 and NSE: SMSPHARMA.

SMS Pharmaceuticals reported revenue of ₹886.87 Cr for FY 2025-26 (up 13.3% YoY) based on consolidated financials.

SMS Pharmaceuticals has 8 current directors:

The GSTIN of SMS Pharmaceuticals is 36AADCS2221D1ZX, registered in Telangana. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 36AADCS2221D2ZW (Telangana), 37AADCS2221D1ZV (Andhra Pradesh).

The CIN (Corporate Identification Number) of SMS Pharmaceuticals is L24239TG1987PLC008066. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. SMS Pharmaceuticals is listed on both BSE (code: 532815) and NSE (symbol: SMSPHARMA).

SMS Pharmaceuticals has 76 court cases on record: 45 filed by the company and 27 filed against it. 10 are pending. Most are in the high courts.

SMS Pharmaceuticals was incorporated on 14 December 1987, making it 39+ years old. It is registered with the Registrar of Companies, Hyderabad.

SMS Pharmaceuticals has 52 deals on record (50 market trades, 1 acquisition, 1 ipo); the latest was in November 2025.

The peers of SMS Pharmaceuticals by revenue are Virupaksha Organics Limited, Abil Chempharma Private Limited, Symed Labs Limited, Synokem Pharmaceuticals Limited, Sterile India Private Limited and 5 more, all in the Pharma industry (API Manufacturers, Pharmaceuticals).

Shanti Sree Bolleni was appointed as Director on 12 Aug 2024. Sunkara Venkata Satya Shiva Prasad was appointed as Director on 12 Aug 2024. Suresh Kumar Gangavarapu was appointed as Director on 12 Aug 2024. SMS Pharmaceuticals has 40 board changes on record in total.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available